Loading...
•
Sep 30, 2021
Blueprint Medicines Q3 2021 Earnings Report
Blueprint Medicines reported strong AYVAKIT launch in advanced SM and raised guidance for 2021 total revenue.
Key Takeaways
Blueprint Medicines reported third quarter 2021 financial results with strong commercial adoption of AYVAKIT and GAVRETO. The company raised its full year 2021 total revenue guidance to $170-$180 million.
AYVAKIT achieved $17.3 million in net product revenues in the first full quarter following U.S. approval for advanced SM.
The company is raising guidance for 2021 total revenue to $170-$180 million.
Broad clinical pipeline is advancing toward multiple key data readouts in 2022.
Topline data from the PIONEER trial of AYVAKIT in non-advanced systemic mastocytosis is expected in mid-2022.
Forward Guidance
The company expects to report full year 2021 total revenues in the range of $170-$180 million, based on product revenue growth and strong collaboration execution with multiple milestone payments anticipated during the fourth quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...